• Pratibha Rani Deparatment of Medical Laboratory Sciences, Lovely Professional University, Phagwara - 144 411, Punjab, India
  • Kamaldeep Singh Department of Medical Laboratory Sciences, C.T Group of Institute, Shahpur, Jalandhar, Punjab, India.
  • Anania Arjuna Deparatment of Medical Laboratory Sciences, Lovely Professional University, Phagwara - 144 411, Punjab, India
  • Savita Devi Deparatment of Medical Laboratory Sciences, Lovely Professional University, Phagwara - 144 411, Punjab, India



Prostate cancer, Radical prostatectomy, Epidemiology and infection


Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men. Prostate-specific antigen (PSA) is the biomarker used for the screening of prostate cancer and other prostate-related problems. Not only the genetic factors are involved dietary factors, environmental factors but also responsible for the development of prostate cancer. Risk factors such as family history, age, chemical exposure, infection, and smoking are at the peak point for the development of prostate disease. Advanced age is one of the main risk factors. Radical prostatectomy is the most common therapy for small group of patients with high-grade tumors. Early screening of PSA reduces the incidence rate of prostate cancer. Mostly prostate abnormalities are seen in among male patients above the age of 50 years or older. In worldwide population, the epidemiology of prostate cancer is high in western countries and less in Asian countries.


Download data is not yet available.


Aumüller G. Functional morphology of the prostate. Urologe A 1989;28:306-10.

Leissner KH, Tisell LE. The weight of the human prostate. Scand J Urol Nephrol 1979;13:137-42.

Kumar VL, Majumder PK. Prostate gland: Structure, functions and regulation. Int Urol Nephrol 1995;27:231-43.

Mc Neal J. The anatomic heterogeneity of the prostate. In: Progress in Clinical and Biological Research. New York: Alan R. Liss; 1990. p. 149-60.

Shipley LA, Illius AW, Danell K, Hobbs NT, Spalinger DE. Predicting bite size selection of mammalian herbivores: A test of a general model of diet optimization. Oikos 1999;84:55-68.

Aumüller G, Seitz J. Protein secretion and secretory processes in male accessory sex glands. Int Rev Cytol 1990;121:127-231.

Blandy JP, Lytton B. The Prostate. London: Butterworths; 1980. p. 68-76.

Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL, et al. Central zone carcinoma of the prostate gland: A distinct tumor type with poor prognostic features. J Urol 2008;179:1762-7.

Gabriel J. The Biology of Cancer. 2nd ed. Hoboken NJ: Wiley; 1990. p. 212-9.

Walter J. Cancer and Radiotherapy: A Short Guide for Nurses and Medical Students. 2nd ed. Edinburgh: Churchill Livingstone; 1987.

Raguvaran R, Rajkumar K, Singh S. Factors influencing prostate cancer. Int J Pharm Pharm Sci 2014;6:33-5.

Ayala AG, Ro JY. Prostatic intraepithelial neoplasia: Recent advances. Arch Pathol Lab Med 2007;131:1257-66.

Lipski BA, Garcia RL, Brawer MK. Prostatic intraepithelial neoplasia: Significance and management. Semin Urol Oncol 1996;14:149-55.

Damber JE, Aus G. Prostate cancer. Lancet 2003;371:1710-21.

Tracey E, Chen S, Baker D, Bishop J, Jelfs P. Cancer in New South Wales, Incidence and Mortality Report Cancer Institute NSW: Central Cancer Registry; 2006.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.

Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-15.

Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: Review 2007. Urology 2007;70:3-8.

Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61:5038-44.

Ponder BA. Cancer genetics. Nature 2001;411:336-41.

Kinzler KW. Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1986;87:159-70.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.

Devi S, Singh K. Risk factors, prevalence and diagnosis of hutchison gilford syndrome with special reference to case reports. Int J Pharm Pharm Sci 2003;9:1-5.

Goodsell DS. The molecular perspective: The ras oncogene. Stem Cells 1997;17:235-6.

Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991;253:562-5.

Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S 1997;68:820-3.

Macleod K. Tumor suppressor genes. Curr Opin Genet Dev 2001;10:8193.

Jorde LB. Medical Genetics. 2nd ed. [Rev.] ed. St. Louis, Mo. London: Mosby; 2000. p. 591-8.

Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP, et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992;70:291-301.

Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.

Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ, et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004;61:124-31.

Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, et al. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000;42:45-55.

Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, et al. Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997;30:117-29.

Royuela M, de Miguel MP, Bethencourt FR, Sánchez-Chapado M, Fraile B, Arenas MI, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001;168:447-54.

Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW,McConnell JD, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 1994;152:433-7.

Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, et al. Study design of the medical therapy of prostatic symptoms (MTOPS) trial. Control Clin Trials 2003;24:224-43.

Sandhu JS, Te AE. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 2004;5:274-9.

Jemal AT, Murray E, Ward A, Samuels RC, Tiwari A, Ghafoor EJ, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.

Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.

Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995;153:1085-96.

Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002;89:230-40.

Massagué J. Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem 1990;265:21393-6.

Yang Y, Chisholm GD, Habib FK. Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: Their relationships with tissue androgen levels. Br J Cancer 1993;67:152-5.

Glynne-Jones E, Goddard L, Harper ME. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 1996;27:688-94.

Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.

Ropiquet F, Giri D, Lamb DJ, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999;162:595-9.

Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O, et al. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 1990;16:71-80.

Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-5.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem 1992;16H Suppl:54-61.

Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC, et al. Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum Pathol 1993;24:4-9.

Perry KT, Anthony CT, Steiner MS. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 1997;33:133-40.

Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111:731-41.

Nilsen-Hamilton M. Transforming growth factor-beta and its actions on cellular growth and differentiation. Curr Top Dev Biol 1990;24:95-136.

Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A 1990;87:1486-90.

Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 1992;99:1-7.

Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-61.

Steiner MS, Barrack ER. Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.

Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A 1990;87:7678-82.

Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 1996;271:H2520-8.

Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-8.

Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. Int J Cancer 1999;80:868-74.

Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001;165:688-93.

Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35:165-77.

Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-6.

Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: Apopulation-based, case-control study. JNatl Cancer Inst 1998;90:911-5.

McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 1995;45:729-44.

Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.

Watt KW, Lee PJ, M’Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986;83:3166-70.

Bélanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate 1995;27:187-97.

Graves HC. Nonprostatic sources of prostate-specific antigen: Asteroid hormone-dependent phenomenon? Clin Chem 1995;41:7-9.

Hendry WF. Recent Advances in Urology/Andrology. Edinburgh: Churchill Livingstone; 1981.

Goldfarb DA, Stein BS, Shamszadeh M, Petersen RO. Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J Urol 1986;136:1266-9.

Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40:4658-62.

Qesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:905-23.

Kantoff PW, Talcott JA. The prostate specific antigen. Its use as a tumor marker for prostate cancer. Hematol Oncol Clin North Am 1994;8:555-72.

Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update 1994. J Urol 1994;152:1358-68.

Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995;28:221-41.

Wang MC, Valenzuela LA, Murphy GP, Chu TM. A simplified purification procedure for human prostate antigen. Oncology 1982;39:1-5.

Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.

Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am 2001;1:191-200.

Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.

Sneyd MJ, Cox B, Paul C, Skegg DC. PSA testing and digital rectal examination in New Zealand. Aust N Z J Public Health 2003;27:502-6.

Villers A, Rébillard X, Soulié M, Davin JL, Coloby P, Moreau JL, et al. Prostate cancer screening. Prog Urol 2003;13:209-14.

Ablin RJ. Aretrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 1997;123:583-94.

Mikuz G. Pathology of prostate cancer. Old problems and new facts. Adv Clin Path 1997;1:21-34.

Franco OE, Arima K, Yanagawa M, Kawamura J. The usefulness of power doppler ultrasonography for diagnosing prostate cancer: Histological correlation of each biopsy site. BJU Int 2000;85:1049-52.

World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Geneva:World Health Organization; 1977.

Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.

Damber JE. Prostate cancer: Epidemiology and risk factors. Curr Opin Urol 1988;8:375-80.

Gann PH. Risk factors for prostate cancer. Rev Urol 2002;4 Suppl 5:S3- S10.

Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996;144:1041-7.

Bloom JR, Stewart SL, Oakley Girvan I, Banks PJ, Chang S. Family history, perceived risk, and prostate cancer screening among African American men. Cancer Epidemiol Biomarkers Prev 2006;15:2167-73.

Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.

Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the united states and native Koreans in south korea. Cancer Control 2007;14:78-85.

Tang D, Liu JJ, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, et al. Grilled meat consumption and phIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev 2007;16:803-8.

Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003;12:604-9.

Ferrini RL, Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998;147:750-4.

Dai WS, Gutai JP, Kuller LH, Cauley JA. Cigarette smoking and serum sex hormones in men. Am J Epidemiol 1988;128:796-805.

O’Berg MT, Chen JL, Burke CA, Walrath J, Pell S. Epidemiologic study of workers exposed to acrylonitrile: An update. J Occup Med 1985;27:835-40.

Walrath J, Fayerweather WE, Gilby PG, Pell S. A case-control study of cancer among du pont employees with potential for exposure to dimethylformamide. J Occup Med 1989;31:432-8.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.

Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, Allard A, et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007;96:137-9.

Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 1995;45:476-83.

Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007;177:2151-6.

Rossi D. Localized prostate cancer. Local treatment and what place for lymphadenectomy. Ann Urol (Paris) 2006;40 Suppl 2:S24-8.

Zhao G, Bai XF, Luo DW, Gao DY. Modeling the heat transfer problem for the novel combined cryosurgery and hyperthermia system. Cryo Letters 2006;27:115-26.

Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.

Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-8.

Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.

Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LA, et al. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2005. p. 1975-2000.

Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 2001;23:3-13.

Parkin DM, Whelan SJ, Ferlay J, Teppo L, Thomas BD, editors. Cancer Incidence in Five Continents. Vol. 8. Lyon: IARC Scientific Publications; 2003. p. 155.

Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64, 1.

Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. Epidemiology 1999;10:452-5.



How to Cite

Rani, P., K. Singh, A. Arjuna, and S. Devi. “DETECTION OF PROSTATE CANCER: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 6, June 2018, pp. 25-31, doi:10.22159/ajpcr.2018.v11i6.24739.



Review Article(s)